Grufity logoGrufity logo

Biomarin Pharmaceutical Inc Stock Research

BMRN

97.24USD+1.95(+2.05%)Market Closed

Market Summary

USD97.24+1.95
Market Closed
2.05%

BMRN Alerts

BMRN Stock Price

BMRN RSI Chart

BMRN Valuation

Market Cap

18.1B

Price/Earnings (Trailing)

127.94

Price/Sales (Trailing)

8.64

EV/EBITDA

64.99

Price/Free Cashflow

329.63

BMRN Price/Sales (Trailing)

BMRN Profitability

Operating Margin

76.92%

EBT Margin

7.14%

Return on Equity

3.08%

Return on Assets

2.22%

Free Cashflow Yield

0.3%

BMRN Fundamentals

BMRN Revenue

Revenue (TTM)

2.1B

Revenue Y/Y

19.5%

Revenue Q/Q

6.37%

BMRN Earnings

Earnings (TTM)

141.6M

Earnings Y/Y

99.57%

Earnings Q/Q

96.26%

Price Action

52 Week Range

70.73117.77
(Low)(High)

Last 7 days

5.8%

Last 30 days

-4.3%

Last 90 days

-7.9%

Trailing 12 Months

22.3%

BMRN Financial Health

Current Ratio

4.67

BMRN Investor Care

Shares Dilution (1Y)

1.27%

Diluted EPS (TTM)

0.75

Peers (Alternatives to Biomarin Pharmaceutical)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
129.1B
26.3B
4.25% 2.73%
19.7
4.9
1.32% 11.18%
103.5B
27.3B
2.11% 42.30%
22.53
3.79
-0.09% -26.23%
59.1B
19.3B
6.22% -15.71%
7.07
3.07
4.29% -31.47%
40.1B
10.2B
1.95% 30.37%
13.18
3.95
-7.36% 95.80%
MID-CAP
9.6B
1.5B
-3.77% 7.31%
61.97
6.43
31.34% 72.43%
3.0B
108.5M
-19.30% -32.38%
-9.14
27.47
122.90% -12.19%
2.5B
107.9M
50.18% 65.38%
-5.15
23.14
54.84% 17.36%
2.2B
60.9M
-25.07% -49.29%
-7.55
35.83
17.51% 22.00%
SMALL-CAP
1.3B
112.0M
-4.12% -47.72%
-4.77
11.36
-70.76% -603.77%
989.9M
7.0M
-20.18% 2.82%
-6.31
141.2
131.81% -45.39%
596.3M
2.0B
-28.83% -91.18%
-0.91
0.3
72.89% 62.27%
515.7M
96.3M
-13.40% -86.70%
-1.83
5.35
72.44% -32.79%
283.5M
111.3M
-44.26% -71.33%
-1.47
2.55
0.54% -7.86%
101.5M
107.0K
-2.91% -84.84%
-0.94
949.05
-88.00% -52.91%
25.7M
-
64.06% -80.69%
-0.32
3.21
0.51% -185.61%

Financials for Biomarin Pharmaceutical

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue4.4%2,0962,0081,9121,8801,846
Cost Of Revenue1.6%484476463467471
  S&GA Expenses3.4%854826792780759
  R&D Expenses1.8%650638638641629
Costs and Expenses2.4%1,9461,9001,8541,8501,929
EBITDA42.1%268188146127-
EBITDA Margin36.1%0.13*0.09*0.08*0.07*-
Earnings Before Taxes48.7%15010156.0036.00-75.35
EBT Margin42.5%0.07*0.05*0.03*0.02*-
Interest Expenses-1.4%16.0016.0015.0015.0015.00
Net Income68.7%14284.0054.0039.00-64.08
Net Income Margin61.6%0.07*0.04*0.03*0.02*-
Free Cahsflow-17.1%55.0066.0016.0047.00-
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets1.8%6,3756,2646,1466,0636,005
  Current Assets2.6%2,7512,6832,5182,3942,274
    Cash Equivalents-4.9%725762620605587
  Inventory6.5%894839802786777
  Net PPE2.0%1,0731,0521,0491,0401,035
  Goodwill0%196196196196196
Liabilities4.5%1,7721,6961,6411,6711,739
  Current Liabilities13.0%589521465490546
Shareholder's Equity0.8%4,6034,5694,5004,3914,266
  Retained Earnings0.0%-789-788-777-804-930
  Additional Paid-In Capital1.3%5,4055,3365,2735,2065,192
Accumulated Depreciation2.7%782762741721-
Shares Outstanding0.2%186186185185184
Cashflow (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-2.4%176180119146305
  Share Based Compensation1.5%196193188196197
Cashflow From Investing3.4%-20.03-20.74-117-207-366
Cashflow From Financing-23.3%-18.65-15.12-23.69-0.96-0.05
  Buy BacksNaN%0.000.00---

Risks for BMRN

What is the probability of a big loss on BMRN?

64.6%


Probability that Biomarin Pharmaceutical stock will be more than 20% underwater in next one year

30%


Probability that Biomarin Pharmaceutical stock will be more than 30% underwater in next one year.

18.5%


Probability that Biomarin Pharmaceutical stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BMRN drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Biomarin Pharmaceutical was unfortunately bought at previous high price.

Drawdowns

Returns for BMRN

Cumulative Returns on BMRN

4.5%


10-Year Cumulative Returns

2.1%


7-Year Cumulative Returns

3.3%


5-Year Cumulative Returns

4.9%


3-Year Cumulative Returns

What are the long-term rolling returns for BMRN?

FIve years rolling returns for Biomarin Pharmaceutical.

Annualized Returns

Which funds bought or sold BMRN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-27
Neo Ivy Capital Management
sold off
-100
-68,000
-
-%
2023-03-23
MetLife Investment Management, LLC
added
0.47
72,924
394,711
-%
2023-03-17
American Portfolios Advisors
reduced
-21.96
-9,058
35,858
-%
2023-03-15
B. Riley Wealth Advisors, Inc.
new
-
271,351
271,351
0.01%
2023-03-10
BAILLIE GIFFORD & CO
unchanged
-
1,486
8,486
-%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
added
2.7
15,822,600
78,168,600
0.09%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-48.3
-31,873,000
54,541,000
0.27%
2023-03-02
OLIVER LAGORE VANVALIN INVESTMENT GROUP
unchanged
-
1,175
5,175
-%
2023-02-28
Voya Investment Management LLC
added
5.08
1,750,370
7,937,370
0.01%
2023-02-24
National Pension Service
reduced
-4.35
3,893,290
27,661,000
0.05%

1–10 of 40

Latest Funds Activity

Are funds buying BMRN calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own BMRN
No. of Funds

Biomarin Pharmaceutical News

Best Stocks

Activist Investor Carl Icahn Urges Investigation into Illuminas Board ....

Best Stocks,
28 hours ago

Nasdaq

Investor's Business Daily

Investor's Business Daily

Schedule 13G FIlings of Biomarin Pharmaceutical

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
dodge & cox
7.7%
14,383,663
SC 13G/A
Feb 13, 2023
capital research global investors
3.0%
5,651,001
SC 13G/A
Feb 09, 2023
primecap management co/ca/
9.46%
17,580,859
SC 13G/A
Feb 09, 2023
vanguard group inc
9.34%
17,365,080
SC 13G/A
Feb 03, 2023
blackrock inc.
8.2%
15,206,690
SC 13G/A
Mar 11, 2022
blackrock inc.
7.6%
14,021,292
SC 13G/A
Feb 14, 2022
dodge & cox
8.1%
14,825,049
SC 13G/A
Feb 10, 2022
primecap management co/ca/
9.7%
17,804,780
SC 13G/A
Feb 09, 2022
vanguard group inc
8.91%
16,351,031
SC 13G/A
Feb 08, 2022
blackrock inc.
7.6%
14,021,292
SC 13G

BMRN Fair Value

Biomarin Pharmaceutical fair value in different scenarios

The table shows the Fair Value estimates for Biomarin Pharmaceutical for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

23.66

-75.67%

28.40

-70.79%

38.90

-60.00%

49.62

-48.97%

60.19

-38.10%
Current Inflation

22.20

-77.17%

26.25

-73.00%

35.14

-63.86%

44.14

-54.61%

53.00

-45.50%
Very High Inflation

20.39

-79.03%

23.65

-75.68%

30.70

-68.43%

37.76

-61.17%

44.70

-54.03%

Historical Biomarin Pharmaceutical Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Biomarin Pharmaceutical

View All Filings
Date Filed Form Type Document
Mar 17, 2023
4
Insider Trading
Mar 17, 2023
4
Insider Trading
Mar 17, 2023
4
Insider Trading
Mar 17, 2023
4
Insider Trading
Mar 17, 2023
4
Insider Trading
Mar 17, 2023
4
Insider Trading
Mar 17, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 13, 2023
144
Notice of Insider Sale Intent
Mar 10, 2023
144
Notice of Insider Sale Intent

Latest Insider Trading transactions for BMRN

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-16
Mueller Brian
sold (taxes)
-371,118
93.41
-3,973
evp, chief financial officer
2023-03-16
Davis George Eric
sold (taxes)
-1,864,180
93.41
-19,957
evp, chief legal officer
2023-03-16
Ajer Jeffrey Robert
sold (taxes)
-1,915,840
93.41
-20,510
evp, chief commercial officer
2023-03-16
BIENAIME JEAN JACQUES
sold (taxes)
-8,278,270
93.41
-88,623
chief executive officer
2023-03-16
FUCHS HENRY J
sold (taxes)
-3,362,760
93.41
-36,000
president, worldwide r&d
2023-03-15
BIENAIME JEAN JACQUES
acquired
-
-
36,100
chief executive officer
2023-03-15
Davis George Eric
acquired
-
-
8,900
evp, chief legal officer
2023-03-15
Burkhart Erin
acquired
-
-
3,760
gvp, chief accounting officer
2023-03-15
FUCHS HENRY J
sold (taxes)
-421,064
87.74
-4,799
president, worldwide r&d
2023-03-15
Ajer Jeffrey Robert
acquired
-
-
10,110
evp, chief commercial officer

1–10 of 50

Jean-Jacques Bienaimé
3040
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

BMRN Income Statement

2022-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
[1]
REVENUES:   
Total revenues$ 2,096,039$ 1,846,275$ 1,860,455
OPERATING EXPENSES:   
Cost of sales483,669470,515524,272
Research and development649,606628,793628,116
Selling, general and administrative854,009759,375737,669
Intangible asset amortization and contingent consideration67,19369,93366,658
Gain on sale of nonfinancial assets, net(108,000)0(52,820)
Total operating expenses1,946,4771,928,6161,903,895
INCOME (LOSS) FROM OPERATIONS149,562(82,341)(43,440)
Interest income18,03410,48216,610
Interest expense(15,970)(15,337)(29,309)
Other income (expense), net(2,050)11,8467,142
INCOME (LOSS) BEFORE INCOME TAXES149,576(75,350)(48,997)
Provision for (benefit from) income taxes8,015(11,270)(903,026)
NET INCOME (LOSS)$ 141,561$ (64,080)$ 854,029[2],[3]
EARNINGS (LOSS) PER SHARE, BASIC (in dollars per share)$ 0.76$ (0.35)$ 4.72
EARNINGS (LOSS) PER SHARE, DILUTED (in dollars per share)$ 0.75$ (0.35)$ 4.50
Weighted-average common shares outstanding, basic (in shares)185,266182,852180,804
Weighted average common shares outstanding, diluted (in shares)188,963182,852191,678
Net product revenues   
REVENUES:   
Total revenues$ 2,042,025$ 1,783,498$ 1,805,861
Royalty and other revenues   
REVENUES:   
Total revenues$ 54,014$ 62,777$ 54,594
[1]Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note 1 to these Consolidated Financial Statements for details.
[2]Certain December 31, 2020 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note 1 to these Consolidated Financial Statements for details.
[3]December 31, 2020 Net Income has been corrected for an immaterial error identified in the third quarter of 2022. See Note 1 to these Consolidated Financial Statements for details.

BMRN Balance Sheet

2022-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
[1]
Current assets:  
Cash and cash equivalents$ 724,531$ 587,276
Short-term investments567,006426,599
Accounts receivable, net461,316373,399
Inventory894,083776,669
Other current assets104,521110,442
Total current assets2,751,4572,274,385
Noncurrent assets:  
Long-term investments333,835507,793
Property, plant and equipment, net1,073,3661,035,461
Intangible assets, net338,569388,652
Goodwill196,199196,199
Deferred tax assets1,505,4121,450,161
Other assets176,236152,121
Total assets6,375,0746,004,772
Current liabilities:  
Accounts payable and accrued liabilities572,959498,265
Short-term contingent consideration15,92548,232
Total current liabilities588,884546,497
Noncurrent liabilities:  
Long-term convertible debt, net1,083,0191,079,077
Long-term contingent consideration015,167
Other long-term liabilities100,01598,362
Total liabilities1,771,9181,739,103
Stockholders’ equity:  
Common stock, $0.001 par value: 500,000,000 shares authorized; 186,250,719 and 183,912,514 shares issued and outstanding, respectively186184
Additional paid-in capital5,404,8955,191,502
Company common stock held by the Nonqualified Deferred Compensation Plan(8,859)(9,689)
Accumulated other comprehensive income (loss)(3,867)14,432
Accumulated deficit(789,199)(930,760)
Total stockholders’ equity4,603,1564,265,669
Total liabilities and stockholders’ equity$ 6,375,074$ 6,004,772
[1]Certain December 31, 2021 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note 1 to these Consolidated Financial Statements for details.